PBAC's latest decision on Pneumococcal polysaccharide conjugate vaccine, 13-valent: Noted (2018). Considered for Prevention of pneumococcal disease (community-acquired pneumonia and invasive pneumococcal disease) in children aged ≥5 to <15 years at increased risk, individuals aged ≥15 to <65 years at increased risk, and Indigenous adults aged ≥25 years.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2010
Submissions
3
2010 → 2018
Eligible population
Children aged ≥5 to <15 years at increased risk of pneumococcal disease; individuals aged ≥15 to <65 years with at-risk conditions; and Indigenous adults aged ≥25 years regardless of risk status.
Cost-minimisation analysis; no ICER calculated. The submission was based on cost-effectiveness compared with 23vPPV, but the PBAC's outcome section does not provide a numeric ICER.